— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share
— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018
— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin
— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor
Most Popular
FDX Earnings: FedEx Q1 adjusted earnings drop; revenue up 5%
Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decline in first-quarter adjusted earnings, despite an increase in revenues. The company also provided guidance for fiscal 2023. Net income, adjusted
Key highlights from Darden Restaurants (DRI) Q1 2023 earnings results
Darden Restaurants, Inc. (NYSE:DRI) reported first quarter 2023 earnings results. Total sales increased 6.1% year-over-year to $2.4 billion, driven by blended same-restaurant sales growth of 4.2%. Net earnings amounted to
ACN Earnings: Key quarterly highlights from Accenture’s Q4 2022 financial results
Accenture (NYSE: ACN) reported fourth quarter 2022 earnings results today. Total revenues were $15.4 billion, up 15% year-over-year in US dollars and up 22.4% in local currency. Net income attributable
